In their work, a novel multifunctional theranostic nanoplatform—Tam-Bi2S3@mPS—was engineered to address prevailing limitations such as inefficient tumor accumulation and complex modification procedures.85 This core–shell nanocomposite consisted of rod-like Bi2S3 nanoparticles (a high atomic number material known for strong X-ray attenuation), encapsulated in mesoporous silica (mPS), loaded with doxorubicin (DOX), and surface-conjugated with trastuzumab (Tam), a monoclonal antibody targeting HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.